Anthocyanin-Rich Freeze-Dried Berry Supplementation in Patients Undergoing Colorectal Cancer Treatment: A Prospective Single-Arm Pilot Study of Tolerability and Longitudinal Inflammatory Biomarker Changes
6 affiliations
- 1Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-530 Krakow, Poland
- 2Department of Clinical Oncology, St Luke’s Hospital, 33-100 Tarnow, Poland
- 3Bioengineering and Cell Imaging Laboratory, Center for the Development of Therapies for Civilization and Age-Related Diseases, Jagiellonian University Medical College, 31-066 Krakow, Poland
- 4Department of Food Chemistry and Nutrition, Jagiellonian University Medical College, 30-688 Krakow, Poland
- 5Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Garncarska 11, 31-115 Krakow, Poland
- 6Department of Endocrine Surgery, Jagiellonian University Medical College, 31-501 Krakow, Poland
Abstract
Background/Objectives: Anthocyanin-rich foods and supplements have shown anti-inflammatory activity in experimental studies, but clinical evidence in patients with colorectal cancer (CRC) remains limited. This exploratory pilot study evaluated longitudinal changes in systemic inflammatory biomarkers and the feasibility and tolerability of anthocyanin-rich berry supplementation during CRC treatment. Methods: In this prospective, open-label interventional study, 50 patients with CRC received an anthocyanin-rich freeze-dried whole-berry supplement (estimated anthocyanin intake of approximately 600–700 mg/day) for 21 consecutive days before initiation of oncological treatment and were followed for 12 weeks. Twenty non-cancer individuals served exclusively as a baseline comparator group. The comparator group was used only for baseline comparisons and not for longitudinal assessment of treatment effects. Clinical and laboratory assessments were performed at baseline, Week 4 (before initiation of oncological treatment), and Week 12 (during standard oncological treatment). Longitudinal changes in inflammatory and biochemical biomarkers were analyzed using non-parametric methods. Results: Median CRP concentrations decreased significantly during follow-up (n = 43), from 20.4 mg/L at baseline to 5.2 mg/L at Week 4 (following supplementation but before initiation of oncological treatment), and to 3.0 mg/L at Week 12 (during standard oncological treatment, p < 0.001). Significant longitudinal changes were also observed in interleukin-1α (IL-1α) net median fluorescence intensity (Net MFI), tumour necrosis factor-α (TNF-α) Net MFI, and interleukin-6 (IL-6) (n = 39). The supplement was generally well-tolerated among participants with available tolerability data (n = 47). Conclusions: A 21-day course of anthocyanin-rich berry supplementation was generally well-tolerated in patients with colorectal cancer. Longitudinal changes in systemic inflammatory biomarkers were observed during follow-up. Because the study did not include a longitudinal CRC control group and participants continued standard oncological treatment, these findings should be considered exploratory and cannot establish that the observed biomarker changes were caused by the supplementation. The observed biomarker patterns are hypothesis-generating and warrant confirmation in adequately powered controlled studies to determine whether anthocyanin-rich berry supplementation influences systemic inflammatory biomarkers in patients with CRC.
Related
- The Effects of Combined Caffeine and Sodium Bicarbonate Supplementation on Exercise Performance, Physiological Responses, and Gastrointestinal Tolerability: A Systematic Review and Meta-Analysis
- Anthocyanin-Rich Aronia melanocarpa Supplementation Modulates Intestinal Barrier Biomarkers and Stress-Axis Response in a Randomized Controlled Trial
- A Poly‐L‐Lactic Acid Formulation for Nasolabial Fold Correction: Handling, Tolerability and Effectiveness in a Prospective Observational Study
- Safety and tolerability of rapid vericiguat initiation and titration alongside GDMT optimization in HFrEF: a prospective cohort study.
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
BibTeX
@article{jaglarzbialy2026anthocyaninrich,
title = {{Anthocyanin-Rich Freeze-Dried Berry Supplementation in Patients Undergoing Colorectal Cancer Treatment: A Prospective Single-Arm Pilot Study of Tolerability and Longitudinal Inflammatory Biomarker Changes}},
author = {Katarzyna Jaglarz-Biały and Marcin Surmiak and Mirosław Krośniak and Mirosława Püsküllüoğlu and Aleksander Konturek},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18213571},
url = {https://www.mdpi.com/2072-6643/18/21/3571},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Anthocyanin-Rich Freeze-Dried Berry Supplementation in Patients Undergoing Colorectal Cancer Treatment: A Prospective Single-Arm Pilot Study of Tolerability and Longitudinal Inflammatory Biomarker Changes
AU - Katarzyna Jaglarz-Biały
AU - Marcin Surmiak
AU - Mirosław Krośniak
AU - Mirosława Püsküllüoğlu
AU - Aleksander Konturek
PY - 2026
DA - 2026/10/29
JO - Nutrients
DO - 10.3390/nu18213571
UR - https://www.mdpi.com/2072-6643/18/21/3571
AB - Background/Objectives: Anthocyanin-rich foods and supplements have shown anti-inflammatory activity in experimental studies, but clinical evidence in patients with colorectal cancer (CRC) remains limited. This exploratory pilot study evaluated longitudinal changes in systemic inflammatory biomarkers and the feasibility and tolerability of anthocyanin-rich berry supplementation during CRC treatment. Methods: In this prospective, open-label interventional study, 50 patients with CRC received an anthocyanin-rich freeze-dried whole-berry supplement (estimated anthocyanin intake of approximately 600–700 mg/day) for 21 consecutive days before initiation of oncological treatment and were followed for 12 weeks. Twenty non-cancer individuals served exclusively as a baseline comparator group. The comparator group was used only for baseline comparisons and not for longitudinal assessment of treatment effects. Clinical and laboratory assessments were performed at baseline, Week 4 (before initiation of oncological treatment), and Week 12 (during standard oncological treatment). Longitudinal changes in inflammatory and biochemical biomarkers were analyzed using non-parametric methods. Results: Median CRP concentrations decreased significantly during follow-up (n = 43), from 20.4 mg/L at baseline to 5.2 mg/L at Week 4 (following supplementation but before initiation of oncological treatment), and to 3.0 mg/L at Week 12 (during standard oncological treatment, p < 0.001). Significant longitudinal changes were also observed in interleukin-1α (IL-1α) net median fluorescence intensity (Net MFI), tumour necrosis factor-α (TNF-α) Net MFI, and interleukin-6 (IL-6) (n = 39). The supplement was generally well-tolerated among participants with available tolerability data (n = 47). Conclusions: A 21-day course of anthocyanin-rich berry supplementation was generally well-tolerated in patients with colorectal cancer. Longitudinal changes in systemic inflammatory biomarkers were observed during follow-up. Because the study did not include a longitudinal CRC control group and participants continued standard oncological treatment, these findings should be considered exploratory and cannot establish that the observed biomarker changes were caused by the supplementation. The observed biomarker patterns are hypothesis-generating and warrant confirmation in adequately powered controlled studies to determine whether anthocyanin-rich berry supplementation influences systemic inflammatory biomarkers in patients with CRC.
SN - 2072-6643
ER -